|Bid||4.2300 x 800|
|Ask||5.0900 x 1100|
|Day's Range||4.7300 - 5.0100|
|52 Week Range||1.9000 - 10.5400|
|Beta (5Y Monthly)||3.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In this article we are going to estimate the intrinsic value of Aspira Women's Health Inc. ( NASDAQ:AWH ) by projecting...
Bioanalytical company Aspira Women’s Health has entered into an agreement with Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Medical University Lodz to study their microRNA technology with Aspira’s solutions. Aspira Women’s Health (AWH) will evaluate the combination of these two technologies to develop ovarian cancer detection tests. Shares of the company jumped about 32% in Thursday’s extended trading session. Aspira’s Chief Scientific Officer, Lesley Northrop, Ph.D., FACMG, said, “Over the past 10 years, Aspira has been actively developing and evaluating numerous technologies that will advance early detection of ovarian cancer.” Northrop further added, “With our focused expertise and experience in multi-modality detection of ovarian cancer risk, we have the foundation to implement a liquid biopsy test specific to early stage disease detection.” Additionally, the company came out with its 4Q results. It posted a net loss of $0.58 per share, which was wider than analysts’ expectations of a net loss of $0.04 per share. Revenues, driven by higher test volumes, increased 10.7% year-over-year to $1.45 million, topping analysts’ estimates by $0.15 million. (See Aspira Women’s Health stock analysis on TipRanks) Recently, Cantor Fitzgerald analyst Kyle Mikson gave the stock a Buy rating with a price target of $10 (49% upside potential). Mikson thinks Aspira’s OVA1plus test “could become the standard of care” and the company’s product pipeline has “significant potential revenue opportunity.” Aspira scores a 6 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock may perform in line with the broader market. Shares have rallied about 852.3% over the past year. Related News: ViacomCBS Drops 23% After Pricing New $3B Stock Sale Evolus Slips 10% On Wider-Than-Expected 4Q Loss Winnebago Crushes 2Q Estimates On Strong Consumer Demand More recent articles from Smarter Analyst: NextDecade Shares Jump 23% After Hours On Carbon Storage Agreement Lamb Weston To Expand French Fry Capacity in China Annaly Capital To Sell Commercial Real Estate Unit For $2.33 Billion BWX Tech Clinches $28 Million Defense Contract